Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- RE-IORT01Independent statistical analysis of Intraoperative Radiotherapy After Local Recurrence in Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02386371).
- Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size…
- REACH 5Independent statistical analysis of Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant: primary endpoint results, effect estimate with confidence…
- Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244: Complete Statistical AnalysisIndependent statistical analysis of Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244: primary endpoint results, effect estimate with confidence interval, sample-size…
- REACTIndependent statistical analysis of Safety and Efficacy of Ranibizumab for Diabetic Macular Edema: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01982435).
- READERIndependent statistical analysis of A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Reader Study to Demonstrate That Use of ClearRead Confirm is Superior to the Use Standard AP/PA X-ray Image: Complete Statistical AnalysisIndependent statistical analysis of Reader Study to Demonstrate That Use of ClearRead Confirm is Superior to the Use Standard AP/PA X-ray Image: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- READY-1Independent statistical analysis of Treatment of Moderate to Severe Glabellar Lines: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04249583).
- READY-2Independent statistical analysis of Treatment of Moderate to Severe Lateral Canthal Lines: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04249687).
- REAL 2Independent statistical analysis of A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth…
- Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study: Complete Statistical AnalysisIndependent statistical analysis of Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Real World Glycemic Effectiveness of Linagliptin: Complete Statistical AnalysisIndependent statistical analysis of Real World Glycemic Effectiveness of Linagliptin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03338803).
- Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program: Complete Statistical AnalysisIndependent statistical analysis of Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01662336).
- Real-time fMRI and Neurofeedback of Brain Networks Mediating Trauma Memory Recall in PTSD: Complete Statistical AnalysisIndependent statistical analysis of Real-time fMRI and Neurofeedback of Brain Networks Mediating Trauma Memory Recall in PTSD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Real-Time fMRI Feedback Effects on Pain Perception: Complete Statistical AnalysisIndependent statistical analysis of Real-Time fMRI Feedback Effects on Pain Perception: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01588197).
- REAL-TIMI 63BIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China: Complete Statistical AnalysisIndependent statistical analysis of Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02668640).
- Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.: Complete Statistical AnalysisIndependent statistical analysis of Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.: primary endpoint results,…
- REAL4Independent statistical analysis of A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4): primary endpoint…
- REALIsM-HFIndependent statistical analysis of REALIsM-HF Pilot Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03507439).
- REASSUREIndependent statistical analysis of Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer: primary endpoint results, effect estimate with confidence interval,…
- REASSURE2Independent statistical analysis of Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Rebif® Pregnancy Registry: Complete Statistical AnalysisIndependent statistical analysis of Rebif® Pregnancy Registry: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00338741).
- Recall by Genotype: Neuropeptide Stimulation: Complete Statistical AnalysisIndependent statistical analysis of Recall by Genotype: Neuropeptide Stimulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05901467).
- ReCePIIndependent statistical analysis of Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients: primary endpoint results, effect estimate with confidence interval, sample-size…
- RECIAIndependent statistical analysis of Multifactorial Approach to Emergent Cerclage: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01114516).
- RECLAIIMIndependent statistical analysis of A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent: Complete Statistical AnalysisIndependent statistical analysis of Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent:…
- Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475: Complete Statistical AnalysisIndependent statistical analysis of Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03049618).
- Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01928030).
- Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers: Complete Statistical AnalysisIndependent statistical analysis of Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer: primary endpoint results, effect…
- Rectal Spacer for Prostate Cancer Radiation Image Guidance: Complete Statistical AnalysisIndependent statistical analysis of Rectal Spacer for Prostate Cancer Radiation Image Guidance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05650021).
- Recurrence Following Nonoperative Management of 1st Episode of Hinchey II Diverticulitis: Complete Statistical AnalysisIndependent statistical analysis of Recurrence Following Nonoperative Management of 1st Episode of Hinchey II Diverticulitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial: Complete Statistical AnalysisIndependent statistical analysis of Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00545181).
- RECYCLINEIndependent statistical analysis of Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease: Complete Statistical AnalysisIndependent statistical analysis of Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Red Cell Storage Duration and Outcomes in Cardiac Surgery: Complete Statistical AnalysisIndependent statistical analysis of Red Cell Storage Duration and Outcomes in Cardiac Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00458783).
- Red-Rubber Catheter to Facilitate Nasotracheal Intubation in Adult Patients: Complete Statistical AnalysisIndependent statistical analysis of Red-Rubber Catheter to Facilitate Nasotracheal Intubation in Adult Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03779984).
- REDEEM-1Independent statistical analysis of BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- REDIRECTIndependent statistical analysis of Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- REDNIVINIndependent statistical analysis of Remifentanil Versus Dexmedetomidine for Post-Cardiac Surgery Patients With Noninvasive Ventilation Intolerance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- REDOIndependent statistical analysis of Medtronic CoreValve REDO Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01051310).
- REDPINEIndependent statistical analysis of Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19): primary endpoint results, effect…
- REDUCIndependent statistical analysis of Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- REDUCE-BPIndependent statistical analysis of Leveraging Electronic Health Record (EHR) Tools to Reduce Health Disparities for Patients With Uncontrolled Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Reduced Exposure Study in Smokers Using THS 2.2 With 5 Days in a Confinement Setting.: Complete Statistical AnalysisIndependent statistical analysis of Reduced Exposure Study in Smokers Using THS 2.2 With 5 Days in a Confinement Setting.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting: Complete Statistical AnalysisIndependent statistical analysis of Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting: primary endpoint results, effect estimate with confidence…
- Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting: Complete Statistical AnalysisIndependent statistical analysis of Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting: primary endpoint results, effect estimate with…
- Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission: Complete Statistical AnalysisIndependent statistical analysis of Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission: primary endpoint results, effect estimate with confidence…